CRISPR makes prostate cancer vulnerable to immunotherapy
The experimental CRISPR Cas13 approach restored an immune signal in mice and made checkpoint therapy more effective, with no detectable off-target effects.
3 Articles
3 Articles
Gene editing may help the immune system find prostate cancer
Researchers at Duke and Rochester universities used gene editing to repair a molecular defect that helps prostate tumors evade immune detection; in mice, the experimental treatment sharply improved immunotherapy, but remains preclinical
CRISPR makes prostate cancer vulnerable to immunotherapy
Scientists used CRISPR to make prostate cancer cells easier for the immune system to detect and destroy. The experimental treatment dramatically improved the effects of immunotherapy in mice and may offer hope for other hard-to-treat tumors.
CRISPR-Based RNA Editing May Boost Immunotherapy Response in Prostate Cancer
As reported on Science Daily, a novel CRISPR-driven RNA editing strategy could help overcome one of the biggest challenges in prostate cancer treatment: resistance to immunotherapy. Researchers have demonstrated that modifying RNA within prostate cancer cells can make tumors more recognizable to the immune system, significantly enhancing the effectiveness of immune checkpoint therapy in preclinical […]
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
